DiaMedica Therapeutics’ (DMAC) “Buy” Rating Reiterated at HC Wainwright

Posted by George Bondi on Aug 14th, 2026

HC Wainwright reissued their buy rating on shares of DiaMedica Therapeutics (NASDAQ:DMAC – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. The brokerage currently has a $12.00 price target on the stock. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.80) EPS, FY2027 earnings at ($0.98) EPS, FY2028 earnings at ($0.60) EPS, FY2029 earnings at ($0.27) EPS and FY2030 earnings at ($0.01) EPS.

A number of other brokerages have also issued reports on DMAC. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Friday, July 17th. Wall Street Zen raised DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

Get Our Latest Research Report on DiaMedica Therapeutics

DiaMedica Therapeutics Price Performance

Shares of DMAC opened at $6.75 on Tuesday. DiaMedica Therapeutics has a 1-year low of $5.14 and a 1-year high of $10.42. The stock has a market cap of $364.03 million, a PE ratio of -9.37 and a beta of 1.01. The firm has a 50-day simple moving average of $6.68 and a two-hundred day simple moving average of $6.92.

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01. As a group, sell-side analysts expect that DiaMedica Therapeutics will post -0.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Millennium Management LLC purchased a new position in shares of DiaMedica Therapeutics in the 3rd quarter valued at about $8,157,000. Geode Capital Management LLC raised its holdings in DiaMedica Therapeutics by 7.4% in the fourth quarter. Geode Capital Management LLC now owns 764,255 shares of the company’s stock valued at $6,085,000 after acquiring an additional 52,437 shares in the last quarter. State Street Corp lifted its stake in DiaMedica Therapeutics by 31.7% in the fourth quarter. State Street Corp now owns 627,771 shares of the company’s stock worth $4,997,000 after acquiring an additional 151,188 shares during the last quarter. Royal Bank of Canada lifted its stake in DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock worth $588,000 after acquiring an additional 154,701 shares during the last quarter. Finally, Osaic Holdings Inc. grew its holdings in DiaMedica Therapeutics by 374.7% during the 2nd quarter. Osaic Holdings Inc. now owns 144,290 shares of the company’s stock worth $563,000 after acquiring an additional 113,893 shares in the last quarter. Institutional investors and hedge funds own 10.12% of the company’s stock.

Key DiaMedica Therapeutics News

Here are the key news stories impacting DiaMedica Therapeutics this week:

Positive Sentiment: Zacks upgraded DMAC to a Rank #2 (Buy). The upgrade reflects growing optimism about DiaMedica’s earnings outlook and could attract additional investor interest. All You Need to Know About DiaMedica Therapeutics Rating Upgrade to Buy
Positive Sentiment: HC Wainwright reiterated its Buy rating and $12 price target. The firm raised its EPS forecasts for the third and fourth quarters of 2026 and for fiscal 2026 through 2028, indicating expectations for narrower losses than previously projected. Its $12 target remains materially above the reference price of $6.75. HC Wainwright Reiterates Buy Rating for DiaMedica Therapeutics
Positive Sentiment: DiaMedica’s second-quarter earnings discussion highlighted its preeclampsia program. The focus on potential clinical opportunities may support the investment case if the company continues to demonstrate progress in development. DiaMedica Therapeutics Q2 2026 Earnings Call Highlights
Neutral Sentiment: Despite the upward estimate revisions, HC Wainwright still expects DiaMedica to report losses through 2030, with the current-year consensus at a loss of $0.86 per share. The earnings call transcript provides additional context for investors assessing development progress and cash needs. DiaMedica Therapeutics Q2 FY2026 Earnings Call Transcript
Negative Sentiment: HC Wainwright lowered its FY2029 EPS forecast to a loss of $0.27 from $0.25 and reduced its FY2030 estimate from a profit of $0.04 to a loss of $0.01. These revisions temper the otherwise constructive outlook and suggest profitability may take longer than previously expected.

DiaMedica Therapeutics Company Profile

(Get Free Report)

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.